nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulfisoxazole—EDNRA—atherosclerosis	0.737	1	CbGaD
Sulfisoxazole—CYP2C9—Rosuvastatin—atherosclerosis	0.0578	0.267	CbGbCtD
Sulfisoxazole—CYP2C9—Simvastatin—atherosclerosis	0.0538	0.248	CbGbCtD
Sulfisoxazole—CYP2C9—Lovastatin—atherosclerosis	0.0526	0.243	CbGbCtD
Sulfisoxazole—CYP2C9—Pravastatin—atherosclerosis	0.0526	0.243	CbGbCtD
Sulfisoxazole—Sulfamethazine—ALB—atherosclerosis	0.000342	0.221	CrCbGaD
Sulfisoxazole—Dapsone—MPO—atherosclerosis	0.000341	0.22	CrCbGaD
Sulfisoxazole—Sulfamerazine—ALB—atherosclerosis	0.000335	0.216	CrCbGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—CNR2—atherosclerosis	0.000291	0.00647	CbGpPWpGaD
Sulfisoxazole—EDNRA—G alpha (q) signalling events—AGTR1—atherosclerosis	0.00029	0.00646	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—KNG1—atherosclerosis	0.000288	0.00642	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Oxidation by Cytochrome P450—CYP27A1—atherosclerosis	0.000287	0.00639	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—AGTR1—atherosclerosis	0.000287	0.00638	CbGpPWpGaD
Sulfisoxazole—EDNRA—Endothelins—MAPK8—atherosclerosis	0.00028	0.00622	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—CCL4—atherosclerosis	0.000279	0.00621	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Arachidonic acid metabolism—ALOX5—atherosclerosis	0.000271	0.00604	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—CCR2—atherosclerosis	0.000264	0.00588	CbGpPWpGaD
Sulfisoxazole—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—atherosclerosis	0.000261	0.00582	CbGpPWpGaD
Sulfisoxazole—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—atherosclerosis	0.00026	0.00578	CbGpPWpGaD
Sulfisoxazole—Sulfamethizole—ALB—atherosclerosis	0.000259	0.167	CrCbGaD
Sulfisoxazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—atherosclerosis	0.000256	0.0057	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP7A1—atherosclerosis	0.000255	0.00568	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL3—atherosclerosis	0.00025	0.00557	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—UTS2—atherosclerosis	0.000249	0.00553	CbGpPWpGaD
Sulfisoxazole—EDNRA—G alpha (q) signalling events—EDN1—atherosclerosis	0.000246	0.00548	CbGpPWpGaD
Sulfisoxazole—EDNRA—Endothelins—MAPK3—atherosclerosis	0.000244	0.00543	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—EDN1—atherosclerosis	0.000243	0.00541	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—CCL5—atherosclerosis	0.000241	0.00537	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—CX3CR1—atherosclerosis	0.000238	0.0053	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—CASR—atherosclerosis	0.000238	0.0053	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP27A1—atherosclerosis	0.000236	0.00525	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—CX3CL1—atherosclerosis	0.000234	0.0052	CbGpPWpGaD
Sulfisoxazole—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—atherosclerosis	0.000232	0.00515	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCR2—atherosclerosis	0.000226	0.00503	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—AGTR1—atherosclerosis	0.000224	0.005	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—CNR2—atherosclerosis	0.000222	0.00493	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—GHRL—atherosclerosis	0.00022	0.00491	CbGpPWpGaD
Sulfisoxazole—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—atherosclerosis	0.00022	0.0049	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—HRH1—atherosclerosis	0.000218	0.00485	CbGpPWpGaD
Sulfisoxazole—EDNRA—G alpha (q) signalling events—AGT—atherosclerosis	0.000204	0.00455	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—AGT—atherosclerosis	0.000202	0.00449	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—HRH1—atherosclerosis	0.000198	0.00441	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	0.000193	0.00431	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—AGTR1—atherosclerosis	0.000192	0.00428	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—CCL3—atherosclerosis	0.00019	0.00424	CbGpPWpGaD
Sulfisoxazole—EDNRA—G alpha (q) signalling events—F2—atherosclerosis	0.000189	0.0042	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—F2—atherosclerosis	0.000186	0.00415	CbGpPWpGaD
Sulfisoxazole—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—atherosclerosis	0.000183	0.00407	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—atherosclerosis	0.000178	0.00395	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—CCR2—atherosclerosis	0.000172	0.00383	CbGpPWpGaD
Sulfisoxazole—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—F2—atherosclerosis	0.000169	0.00376	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—GHRL—atherosclerosis	0.000168	0.00374	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—CCL2—atherosclerosis	0.000166	0.0037	CbGpPWpGaD
Sulfisoxazole—EDNRA—Endothelins—AKT1—atherosclerosis	0.000165	0.00366	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	0.000163	0.00363	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	0.000162	0.0036	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—KNG1—atherosclerosis	0.000147	0.00328	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—atherosclerosis	0.000147	0.00327	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—AGTR1—atherosclerosis	0.000146	0.00326	CbGpPWpGaD
Sulfisoxazole—Sulfamethoxazole—ALB—atherosclerosis	0.000146	0.0939	CrCbGaD
Sulfisoxazole—CYP2C9—Arachidonic acid metabolism—GPX1—atherosclerosis	0.000144	0.00321	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—CCL4—atherosclerosis	0.000143	0.00318	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—UTS2—atherosclerosis	0.00014	0.00313	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Biological oxidations—CYP7A1—atherosclerosis	0.000136	0.00302	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	0.000135	0.00301	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—CASR—atherosclerosis	0.000135	0.003	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metapathway biotransformation—CYP7A1—atherosclerosis	0.000134	0.00298	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—CXCL8—atherosclerosis	0.000131	0.00292	CbGpPWpGaD
Sulfisoxazole—Dapsone—PTGS2—atherosclerosis	0.000128	0.0825	CrCbGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—UTS2—atherosclerosis	0.000128	0.00284	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Biological oxidations—CYP27A1—atherosclerosis	0.000125	0.00279	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—CNR2—atherosclerosis	0.000125	0.00279	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	0.000125	0.00278	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—EDN1—atherosclerosis	0.000124	0.00276	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metapathway biotransformation—CYP27A1—atherosclerosis	0.000124	0.00275	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—CCL5—atherosclerosis	0.000123	0.00274	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—CX3CR1—atherosclerosis	0.000122	0.00272	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—CASR—atherosclerosis	0.000122	0.00272	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—CX3CL1—atherosclerosis	0.00012	0.00267	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—HRH1—atherosclerosis	0.000117	0.0026	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—CNR2—atherosclerosis	0.000114	0.00253	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	0.000111	0.00248	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—AGT—atherosclerosis	0.000103	0.00229	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—CCL3—atherosclerosis	9.77e-05	0.00218	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—CCR2—atherosclerosis	9.73e-05	0.00217	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—F2—atherosclerosis	9.52e-05	0.00212	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—GHRL—atherosclerosis	9.49e-05	0.00211	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—APOA4—atherosclerosis	9.17e-05	0.00204	CbGpPWpGaD
Sulfisoxazole—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—atherosclerosis	9.14e-05	0.00204	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—LDLRAP1—atherosclerosis	8.91e-05	0.00198	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—CCR2—atherosclerosis	8.84e-05	0.00197	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	8.81e-05	0.00196	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—GHRL—atherosclerosis	8.61e-05	0.00192	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—CCL2—atherosclerosis	8.49e-05	0.00189	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Arachidonic acid metabolism—PTGS2—atherosclerosis	8.48e-05	0.00189	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CCL4—atherosclerosis	8.45e-05	0.00188	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PLTP—atherosclerosis	8.38e-05	0.00187	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—KNG1—atherosclerosis	8.33e-05	0.00185	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—AGTR1—atherosclerosis	8.28e-05	0.00184	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—APOA2—atherosclerosis	7.9e-05	0.00176	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—KNG1—atherosclerosis	7.56e-05	0.00168	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—UTS2—atherosclerosis	7.53e-05	0.00168	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—AGTR1—atherosclerosis	7.52e-05	0.00167	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—ABCG8—atherosclerosis	7.27e-05	0.00162	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—LTA4H—atherosclerosis	7.27e-05	0.00162	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CX3CR1—atherosclerosis	7.22e-05	0.00161	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CASR—atherosclerosis	7.22e-05	0.00161	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CX3CL1—atherosclerosis	7.08e-05	0.00158	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—EDN1—atherosclerosis	7.02e-05	0.00156	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—CCL5—atherosclerosis	6.96e-05	0.00155	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CNR2—atherosclerosis	6.71e-05	0.00149	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—CXCL8—atherosclerosis	6.71e-05	0.00149	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—MMP3—atherosclerosis	6.7e-05	0.00149	CbGpPWpGaD
Sulfisoxazole—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	6.69e-05	0.00149	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—PRKCG—atherosclerosis	6.62e-05	0.00147	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—EDN1—atherosclerosis	6.37e-05	0.00142	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—CCL5—atherosclerosis	6.32e-05	0.00141	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—PRKCG—atherosclerosis	6.01e-05	0.00134	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—VWF—atherosclerosis	5.99e-05	0.00133	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—APOC3—atherosclerosis	5.95e-05	0.00132	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—LDLR—atherosclerosis	5.91e-05	0.00132	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—AGT—atherosclerosis	5.82e-05	0.0013	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CCL3—atherosclerosis	5.77e-05	0.00129	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—ABCG1—atherosclerosis	5.74e-05	0.00128	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Biological oxidations—GSTM1—atherosclerosis	5.6e-05	0.00125	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—NCF1—atherosclerosis	5.53e-05	0.00123	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metapathway biotransformation—GSTM1—atherosclerosis	5.52e-05	0.00123	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—FABP4—atherosclerosis	5.4e-05	0.0012	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—LCAT—atherosclerosis	5.4e-05	0.0012	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—F2—atherosclerosis	5.38e-05	0.0012	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—APOA4—atherosclerosis	5.3e-05	0.00118	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—AGT—atherosclerosis	5.29e-05	0.00118	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CCR2—atherosclerosis	5.22e-05	0.00116	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP7A1—atherosclerosis	5.21e-05	0.00116	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CYBA—atherosclerosis	5.2e-05	0.00116	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—PIK3CG—atherosclerosis	5.15e-05	0.00115	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—PLAT—atherosclerosis	5.09e-05	0.00113	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—PARP1—atherosclerosis	5.09e-05	0.00113	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—GHRL—atherosclerosis	5.09e-05	0.00113	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—F2—atherosclerosis	4.89e-05	0.00109	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP27A1—atherosclerosis	4.81e-05	0.00107	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—PIK3CG—atherosclerosis	4.68e-05	0.00104	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—atherosclerosis	4.56e-05	0.00102	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—ALOX5AP—atherosclerosis	4.56e-05	0.00102	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G2A—atherosclerosis	4.56e-05	0.00102	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—APOA2—atherosclerosis	4.56e-05	0.00102	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—ABCG5—atherosclerosis	4.51e-05	0.001	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—KNG1—atherosclerosis	4.47e-05	0.000994	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—AGTR1—atherosclerosis	4.44e-05	0.000988	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—CCL2—atherosclerosis	4.36e-05	0.00097	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—LPA—atherosclerosis	4.35e-05	0.000969	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—PLG—atherosclerosis	4.33e-05	0.000963	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—APOA5—atherosclerosis	4.17e-05	0.000929	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—SOCS3—atherosclerosis	4.1e-05	0.000912	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G1B—atherosclerosis	4.02e-05	0.000894	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—LDLRAP1—atherosclerosis	3.97e-05	0.000883	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—MMP3—atherosclerosis	3.96e-05	0.000881	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—IGF2—atherosclerosis	3.94e-05	0.000877	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—ALOX5—atherosclerosis	3.88e-05	0.000863	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—APOB—atherosclerosis	3.83e-05	0.000851	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—CXCL8—atherosclerosis	3.79e-05	0.000844	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—EDN1—atherosclerosis	3.76e-05	0.000838	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CCL5—atherosclerosis	3.74e-05	0.000831	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—PLTP—atherosclerosis	3.73e-05	0.000831	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—LPL—atherosclerosis	3.65e-05	0.000813	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—PRKCG—atherosclerosis	3.55e-05	0.00079	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—SPP1—atherosclerosis	3.46e-05	0.00077	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—atherosclerosis	3.46e-05	0.00077	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—CXCL8—atherosclerosis	3.44e-05	0.000767	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—APOC3—atherosclerosis	3.44e-05	0.000765	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—LDLR—atherosclerosis	3.42e-05	0.00076	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—CETP—atherosclerosis	3.34e-05	0.000743	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—ABCG8—atherosclerosis	3.24e-05	0.00072	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—LTA4H—atherosclerosis	3.24e-05	0.00072	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—PDGFB—atherosclerosis	3.2e-05	0.000712	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—atherosclerosis	3.19e-05	0.000711	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—AGT—atherosclerosis	3.12e-05	0.000695	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—APOE—atherosclerosis	3.06e-05	0.000681	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—LEP—atherosclerosis	3.06e-05	0.000681	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CAV1—atherosclerosis	3.03e-05	0.000675	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—APOA1—atherosclerosis	3.03e-05	0.000674	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—HMGCR—atherosclerosis	3.02e-05	0.000672	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—ESR1—atherosclerosis	2.92e-05	0.000651	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—F2—atherosclerosis	2.89e-05	0.000643	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—PIK3CG—atherosclerosis	2.76e-05	0.000615	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	2.69e-05	0.000599	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—MAPK3—atherosclerosis	2.65e-05	0.000589	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—INS—atherosclerosis	2.62e-05	0.000582	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CCL2—atherosclerosis	2.57e-05	0.000573	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—ABCG1—atherosclerosis	2.56e-05	0.000569	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—IGF1—atherosclerosis	2.53e-05	0.000563	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—LCAT—atherosclerosis	2.4e-05	0.000535	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—FABP4—atherosclerosis	2.4e-05	0.000535	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—SERPINE1—atherosclerosis	2.4e-05	0.000535	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—APOA4—atherosclerosis	2.36e-05	0.000525	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—CYP7A1—atherosclerosis	2.32e-05	0.000516	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—NOS3—atherosclerosis	2.29e-05	0.00051	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	2.21e-05	0.000492	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—CYP27A1—atherosclerosis	2.14e-05	0.000477	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	2.11e-05	0.00047	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	2.06e-05	0.000458	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CXCL8—atherosclerosis	2.03e-05	0.000453	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—PLA2G2A—atherosclerosis	2.03e-05	0.000452	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—APOA2—atherosclerosis	2.03e-05	0.000452	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—ALOX15—atherosclerosis	2.03e-05	0.000452	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—ALOX5AP—atherosclerosis	2.03e-05	0.000452	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—ABCG5—atherosclerosis	2.01e-05	0.000447	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	2e-05	0.000446	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—AKT1—atherosclerosis	1.97e-05	0.000437	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—LPA—atherosclerosis	1.94e-05	0.000431	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—IL6—atherosclerosis	1.93e-05	0.000431	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—BGN—atherosclerosis	1.88e-05	0.000418	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	1.86e-05	0.000415	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—APOA5—atherosclerosis	1.86e-05	0.000414	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—MMP9—atherosclerosis	1.84e-05	0.00041	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—NFKB1—atherosclerosis	1.82e-05	0.000405	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	1.81e-05	0.000402	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—MAPK8—atherosclerosis	1.79e-05	0.000398	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—PLA2G1B—atherosclerosis	1.79e-05	0.000398	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—AKT1—atherosclerosis	1.78e-05	0.000397	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	1.77e-05	0.000394	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	1.75e-05	0.00039	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	1.75e-05	0.000389	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—ALOX5—atherosclerosis	1.73e-05	0.000385	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—VEGFA—atherosclerosis	1.65e-05	0.000368	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—STAT3—atherosclerosis	1.64e-05	0.000364	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	1.6e-05	0.000355	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—MAPK3—atherosclerosis	1.56e-05	0.000348	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—NAMPT—atherosclerosis	1.55e-05	0.000345	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1.54e-05	0.000343	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—LIPC—atherosclerosis	1.54e-05	0.000343	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—APOC3—atherosclerosis	1.53e-05	0.000341	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—LDLR—atherosclerosis	1.52e-05	0.000339	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—TGFB1—atherosclerosis	1.52e-05	0.000338	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—CETP—atherosclerosis	1.49e-05	0.000331	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—SCARB1—atherosclerosis	1.42e-05	0.000317	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	1.39e-05	0.000308	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—HMGCR—atherosclerosis	1.34e-05	0.000299	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.21e-05	0.00027	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—ABCA1—atherosclerosis	1.2e-05	0.000267	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—IL6—atherosclerosis	1.14e-05	0.000254	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—AKT1—atherosclerosis	1.05e-05	0.000235	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—HMOX1—atherosclerosis	1.03e-05	0.000229	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—APOB—atherosclerosis	9.84e-06	0.000219	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—GSTM1—atherosclerosis	9.57e-06	0.000213	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—LPL—atherosclerosis	9.4e-06	0.000209	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—GPX1—atherosclerosis	9.17e-06	0.000204	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—CD36—atherosclerosis	8.93e-06	0.000199	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—MTHFR—atherosclerosis	8.46e-06	0.000188	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—PPARA—atherosclerosis	8.3e-06	0.000185	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—AGT—atherosclerosis	8.04e-06	0.000179	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—APOE—atherosclerosis	7.88e-06	0.000175	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—CAV1—atherosclerosis	7.8e-06	0.000174	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—APOA1—atherosclerosis	7.79e-06	0.000173	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—PIK3CG—atherosclerosis	7.11e-06	0.000158	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—PPARG—atherosclerosis	6.86e-06	0.000153	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—INS—atherosclerosis	6.73e-06	0.00015	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—ALB—atherosclerosis	6.17e-06	0.000137	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—NOS3—atherosclerosis	5.9e-06	0.000131	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—PTGS2—atherosclerosis	5.4e-06	0.00012	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—AKT1—atherosclerosis	2.71e-06	6.04e-05	CbGpPWpGaD
